z-logo
open-access-imgOpen Access
MAP Kinases and Prostate Cancer
Author(s) -
Gonzalo RodríguezBerriguete,
Benito Fraile,
Pilar Martínez-Onsurbe,
Gabriel Olmedilla,
Ricardo Paniagua,
Mar Royuela
Publication year - 2011
Publication title -
journal of signal transduction
Language(s) - English
Resource type - Journals
eISSN - 2090-1739
pISSN - 2090-1747
DOI - 10.1155/2012/169170
Subject(s) - p38 mitogen activated protein kinases , mapk/erk pathway , medicine , apoptosis , kinase , cancer research , prostate cancer , programmed cell death , prostate , tumor promotion , cell growth , cancer , signal transduction , radioresistance , mitogen activated protein kinase , microbiology and biotechnology , biology , radiation therapy , biochemistry , carcinogenesis
The three major mitogen-activated protein kinases (MAPKs) p38, JNK, and ERK are signal transducers involved in a broad range of cell functions including survival, apoptosis, and cell differentiation. Whereas JNK and p38 have been generally linked to cell death and tumor suppression, ERK plays a prominent role in cell survival and tumor promotion, in response to a broad range of stimuli such as cytokines, growth factors, ultraviolet radiation, hypoxia, or pharmacological compounds. However, there is a growing body of evidence supporting that JNK and p38 also contribute to the development of a number of malignances. In this paper we focus on the involvement of the MAPK pathways in prostate cancer, including the less-known ERK5 pathway, as pro- or antitumor mediators, through their effects on apoptosis, survival, metastatic potential, and androgen-independent growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom